.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,906,898

« Back to Dashboard

Claims for Patent: 8,906,898

Title:Solid forms of ceftolozane
Abstract: Novel solid forms of ceftolozane are described, as well as methods for the preparation and use of these solid forms.
Inventor(s): Hwang; You Seok (Windham, NH), Damour; Nicole Miller (Belmont, MA), Duong; Lisa (Lynn, MA), Jurkauskas; Valdas (Cambridge, MA), Moshos; Kristos Adrian (Belmont, MA), Mudur; Sanjay (Woburn, MA), Ovat; Asli (Maynard, MA), Terracciano; Joseph (Concord, MA), Woertink; Jason (Sudbury, MA)
Assignee: Calixa Therapeutics, Inc. (Lexington, MA)
Application Number:14/289,224
Patent Claims: 1. Solid Form 2 of ceftolozane sulfate that produces an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta.+-.0.2) of 4.4, 8.8. 11.0, 14.9, and 17.7.

2. The solid form of ceftolozane sulfate of claim 1 that produces Raman shift peaks (.+-.5 cm.sup.-1) at about 151 cm.sup.-1, 684 cm.sup.-1, and 802 cm.sup.-1.

3. The solid form of ceftolozane sulfate of claim 1 characterized by a differential scanning calorimetry (DSC) endotherm having a minima at about 105 degrees C.

4. The solid form of ceftolozane sulfate of claim 1, characterized by a thermogravimetric analysis (TGA) with a weight loss of about 6.8% between 25-181 degrees C.

5. The solid form of ceftolozane sulfate of claim 1, characterized by a. a differential scanning calorimetry (DSC) endotherm having a minima at about 105 degrees C.; b. a thermogravimetric analysis (TGA) with a weight loss of about 6.8% between 25-181 degrees C.; and c. Raman shift peaks (.+-.5 cm.sup.-1) at 151 cm.sup.-1, 684 cm.sup.-1, 802 cm.sup.-1, 1174 cm.sup.-1, and 2953 cm.sup.-1.

6. A pharmaceutical composition comprising the solid form of ceftolozane sulfate designated as ceftolozane sulfate Form 2 that produces an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta.+-.0.2) of 4.4, 8.8. 11.0, 14.9, and 17.7.

7. The pharmaceutical composition of claim 6, wherein the ceftolozane sulfate produces Raman shift peaks (.+-.5 cm.sup.-1) at about 151 cm.sup.-1, 684 cm.sup.-1, 802 cm.sup.-1, 1174 cm.sup.-1, and 2953 cm.sup.-1.

8. The pharmaceutical composition of claim 7, further comprising ceftolozane sulfate in a solid form that produces an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta.+-.0.2) of 12.4, 16.4, 22.6, 25.1 and 28.0.

9. The pharmaceutical composition of claim 6, further comprising tazobactam.

10. The pharmaceutical composition of claim 6, further comprising a pharmaceutically acceptable excipient.

11. The pharmaceutical composition of claim 10, wherein the pharmaceutically acceptable excipient is selected from the group consisting of: sodium chloride, L-arginine, citric acid and mixtures thereof.

12. The pharmaceutical composition of claim 11, characterized by one or more of the following: a. a differential scanning calorimetry (DSC) endotherm having a minima at about 105 degrees C.; b. a thermogravimetric analysis (TGA) with a weight loss of about 6.8% between 25-181 degrees C.; and c. Raman shift peaks (.+-.5 cm.sup.-1) at 151 cm.sup.-1, 684 cm.sup.-1, 802 cm.sup.-1, 1174 cm.sup.-1, and 2953 cm.sup.-1.

13. A pharmaceutical composition comprising a lyophilized ceftolozane composition obtained by a process comprising the steps of: a. combining the ceftolozane sulfate in a solid form designated as ceftolozane sulfate Form 2 that produces an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta.+-.0.2) of 4.4, 8.8, 11.0, 14.9, and 17.7, with water, sodium chloride and L-arginine to form an aqueous solution; and b. lyophilizing the aqueous solution to form the lyophilized ceftolozane composition comprising ceftolozane sulfate.

14. The pharmaceutical composition of claim 13, wherein the lyophilization cycle is characterized by one or more of the following characteristics: a. not more than 150 mg ceftolozane free base/g bulk solution concentration, b. no more than 3 cm fill depth, c. freezing to at least -40.degree. C. during the lyophilization cycle, d. drying to no more than 40.degree. C., and e. single- or multi-step drying and setting chamber pressure during the start of primary drying at not more than 400.mu. bar.

15. The pharmaceutical composition of claim 13, further comprising tazobactam.

16. The pharmaceutical composition of claim 15, obtained by a process further comprising combining the lyophilized ceftolozane composition with tazobactam in a fixed dose combination providing about 500 mg of tazobactam active per 1,000 mg of ceftolozane active in the pharmaceutical composition.

17. A pharmaceutical composition comprising a lyophilized ceftolozane composition obtained by a process comprising the steps of: a. combining the ceftolozane sulfate of solid Form 2 that produces an X-ray powder diffraction (XRPD) pattern having diffractions at angles (2 theta.+-.0.2) of 4.4, 8.8. 11.0, 14.9, and 17.7 with water to form an aqueous solution; and b. lyophilizing the aqueous solution to form the lyophilized ceftolozane composition comprising ceftolozane sulfate.

18. The pharmaceutical composition of claim 17, wherein the aqueous solution in step (b) further comprises tazobactam or a pharmaceutically acceptable salt thereof.

19. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition comprises tazobactam sodium.

20. The pharmaceutical composition of claim 17, wherein the aqueous solution in step (b) is lyophilized in the absence of tazobactam.

21. The pharmaceutical composition of claim 17, wherein the pharmaceutical composition comprises the ceftolozane sulfate in an amount providing about 1,000 mg of ceftolozane active.

22. The pharmaceutical composition of claim 21, wherein the pharmaceutical composition further comprises about 500 mg of tazobactam active.

23. The pharmaceutical composition of claim 17, wherein the pharmaceutical composition comprises ceftolozane active and tazobactam active, and the ceftolozane sulfate is present in the pharmaceutical composition in an amount providing 1,000 mg of ceftolozane active per 500 mg of tazobactam active.

24. The pharmaceutical composition of claim 17, wherein the pharmaceutical composition comprises ceftolozane and a beta-lactamase inhibitor compound.

25. The pharmaceutical composition of claim 17, wherein the pharmaceutical composition comprises about 1,000 mg of ceftolozane active and 500 mg of tazobactam active.

26. The pharmaceutical composition of claim 17, obtained by a process further comprising combining the lyophilized ceftolozane composition with tazobactam in a fixed dose combination providing about 500 mg of tazobactam active per 1,000 mg of ceftolozane active in the pharmaceutical composition.

27. The pharmaceutical composition of claim 26, wherein the pharmaceutical composition comprises tazobactam sodium.

28. The pharmaceutical composition of claim 26, wherein the pharmaceutical composition comprises crystalline tazobactam.

29. The pharmaceutical composition of claim 26, wherein the aqueous solution is lyophilized in step (b) with a lyophilization cycle characterized by one or more of the following characteristics: a. not more than 150 mg ceftolozane free base/g bulk solution concentration, b. no more than 3 cm fill depth, c. freezing to at least -40.degree. C. during the lyophilization cycle, d. drying to no more than 40.degree. C., and e. single- or multi-step drying and setting chamber pressure during the start of primary drying at not more than 400.mu. bar.

30. The pharmaceutical composition of claim 26, characterized by one or more of the following: a. a differential scanning calorimetry (DSC) endotherm having a minimia at about 105 degrees C.; b. a thermogravimetric analysis (TGA) with a weight loss of about 6.8% between 25-181 degrees C.; and c. Raman shift peaks (.+-.5 cm.sup.-1) at 151 cm.sup.-1, 684 cm.sup.-1, 802 cm.sup.-1, 1174 cm.sup.-1, and 2953 cm.sup.-1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc